Endo, Inc. (“Endo” or the “Company”) (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc. Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks, and up to $15 million in future payments contingent upon the achievement of certain milestones.
Read the full article: Endo Completes International Pharmaceuticals Business Divestiture //
Source: https://www.prnewswire.com/news-releases/endo-completes-international-pharmaceuticals-business-divestiture-302483838.html